Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Cause Prostatic specific antigen increased? 212 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 212 reports of Prostatic specific antigen increased have been filed in association with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (PLUVICTO). This represents 2.0% of all adverse event reports for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN.

212
Reports of Prostatic specific antigen increased with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
2.0%
of all LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN reports
20
Deaths
19
Hospitalizations

How Dangerous Is Prostatic specific antigen increased From LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN?

Of the 212 reports, 20 (9.4%) resulted in death, 19 (9.0%) required hospitalization, and 1 (0.5%) were considered life-threatening.

Is Prostatic specific antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN. However, 212 reports have been filed with the FAERS database.

What Other Side Effects Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Cause?

General physical health deterioration (4,332) Ill-defined disorder (3,600) Death (1,179) Disease progression (286) Malignant neoplasm progression (251) Laboratory test abnormal (233) Fatigue (177) Anaemia (154) Covid-19 (139) Platelet count decreased (130)

What Other Drugs Cause Prostatic specific antigen increased?

ENZALUTAMIDE (3,731) LEUPROLIDE (2,432) ABIRATERONE (1,581) RADIUM RA-223 DICHLORIDE (449) RELUGOLIX (335) BICALUTAMIDE (322) DOCETAXEL (282) APALUTAMIDE (251) DENOSUMAB (220) OLAPARIB (176)

Which LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Alternatives Have Lower Prostatic specific antigen increased Risk?

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LUTETIUM OXODOTREOTIDE LU-177 LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LUTROPIN ALFA LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYMECYCLINE LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYRICA LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYSERGIDE

Related Pages

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Full Profile All Prostatic specific antigen increased Reports All Drugs Causing Prostatic specific antigen increased LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Demographics